Acadia Healthcare Co Bolsa (NASDAQ: ACHC)

Últimas noticias sobre Acadia Healthcare Co (NASDAQ:ACHC) Bolsa

Acadia Healthcare Co

Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling more than 100 points on Friday.
The Dow traded up 0.26% to 42,285.93 while the NASDAQ fell 0.59% to 18,083.01. The S&amp;P 500 also fell, dropping, 0.25% to 5,731.09.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41065070/micron-to-150-here-are-10-top-analyst-forecasts-for-friday">Micron To $150? Here Are 10 Top Analyst Forecasts For Friday</a>
Leading and Lagging Sectors Energy shares jumped by 1.3% on Friday.
In trading on Friday, information technology shares fell by 1%.
Top Headline
The total number of active U.S. oil rigs fell by four to 484 rigs this week, Baker Hughes Inc reported
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares shot up 16% to $9.36 after the company announced it signed a $54.5 million contract with the United States Air Force Research Lab.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) got a boost, surging 56% to $5.28. Altos Venture reported a 32.5% stake in the company as of September 24 in a 13D filing on Thursday.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares were also up, gaining 12% to $9.75 after Keybanc raised its price target on the stock from $8 to $11.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 19% to $4.07. Seelos announced postponement of its annual meeting of stockholders.</li>
<li>Shares of enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) were down 25% to $4.07 after the company announced the pricing of a $15 million public offering of 4.3 million shares at $3.50 per share.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) was down, falling 16% to $63.46 after the company issued a statement stating they are cooperating fully with the authorities regarding a government investigation.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $68.18 while gold traded down 0.9% at $2,670.50.
Silver traded down 1.4% to $31.88 on Friday, while copper fell 1% to $4.5930.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 gained 0.47%, Germany's DAX climbed 1.22% and France's CAC 40 jumped 0.64%. Spain's IBEX 35 Index rose 0.12%, while London's FTSE 100 rose 0.43%.
The industry confidence indicator in Spain climbed by 2.8 points from the prior month to a reading of -0.7 in September. Industrial producer prices in Italy declined by 0.8% year-over-year in August.
The economic sentiment indicator in the Eurozone slipped to 96.2 in September from 96.5 in August, while services sentiment indicator climbed to a four-month high level of 6.7 in September. The consumer confidence indicator in the Eurozone gained by 0.5 points to -12.9 in September.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 jumping 2.32%, Hong Kong's Hang Seng Index jumping 3.55%, China's Shanghai Composite Index gaining 2.88% and India's BSE Sensex falling 0.31%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month. The People&#8217;s Bank of China slashed the reserve requirement ratio for banks by 50bps.
Economics
<ul>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $905.7 billion in August compared to a revised 0.2% rise in the prior month.</li>
<li>The U.S. trade deficit in goods narrowed to $94.3 billion in August versus a revised $102.8 billion gap in the previous month.</li>
<li>U.S. personal income rose by 0.2% from the prior month to $24.015 trillion in August compared to a 0.3% gain in the previous month.</li>
<li>Personal spending rose by 0.2% month-over-month in August.</li>
<li>The US core PCE price index increased by 0.1% from the prior month in August compared to market estimates of a 0.2% increase and versus the 0.2% gain in the previous month.</li>
<li>The total number of active U.S. oil rigs fell by four to 484 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Equities

News

Eurozone

Commodities

Intraday Update

Trading Ideas

ACHC

IONQ

NVNO

ONCO

RKLB

SEEL

Crude Oil Rises; Onconetix Shares Spike Higher

<h3>Gainers</h3>
<ul>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares rose 53.5% to $5.15 during Friday's regular session. The company's market cap stands at $3.8 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock increased by 31.77% to $0.6. The market value of their outstanding shares is at $29.1 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 22.72% to $1.89. The market value of their outstanding shares is at $11.1 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock moved upwards by 22.69% to $1.19. The market value of their outstanding shares is at $43.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares rose 16.98% to $1.24. The company's market cap stands at $12.6 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares increased by 16.73% to $0.25. The company's market cap stands at $5.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares decreased by 27.0% to $1.49 during Friday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock declined by 24.45% to $3.4. The company's market cap stands at $45.3 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares decreased by 21.54% to $0.47. The market value of their outstanding shares is at $3.5 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 18.43% to $0.77. The company's market cap stands at $14.9 million. </li>
<li>Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares fell 17.41% to $62.49. The company's market cap stands at $5.8 billion. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 15.49% to $2.02. The company's market cap stands at $23.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ESLA

INDP

MYNZ

PSTV

TOVX

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index surging more than 250 points on Friday.
The Dow traded up 0.66% to 42,452.85 while the NASDAQ fell 0.45% to 18,108.42. The S&amp;P 500 also fell, dropping, 0.07% to 5,741.34.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41065070/micron-to-150-here-are-10-top-analyst-forecasts-for-friday">Micron To $150? Here Are 10 Top Analyst Forecasts For Friday</a>
Leading and Lagging Sectors Energy shares jumped by 1.4% on Friday.
In trading on Friday, information technology shares fell by 0.3%.
Top Headline
According to government data released Friday, the Personal Consumption Expenditures (PCE) Price Index increased by 2.2% in August compared to the same period last year. The reading was below the 2.3% analysts were expecting and a drop from July's 2.5%.
The core PCE, which excludes volatile food and energy prices, was 2.7% year-over-year in August, matching analyst expectations and 0.1% higher than July's number.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares shot up 19% to $9.56 after the company announced it signed a $54.5 million contract with the United States Air Force Research Lab.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) got a boost, surging 64% to $5.57. Altos Venture reported a 32.5% stake in the company as of September 24 in a 13D filing on Thursday.</li>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares were also up, gaining 11% to $10.59. Biomea Fusion disclosed that the FDA lifted its clinical hold on BMF-219 in Type 2 and Type 1 diabetes trials. Rodman &amp; Renshaw analyst Tony Butler upgraded Biomea Fusion from Neutral to Buy.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 12% to $4.39. Seelos announced postponement of its annual meeting of stockholders.</li>
<li>Shares of enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) were down 22% to $3.50 after the company announced the pricing of a $15 million public offering of 4.3 million shares at $3.50 per share.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) was down, falling 25% to $56.60 after the company issued a statement stating they are cooperating fully with the authorities regarding a government investigation.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $67.16 while gold traded down 0.3% at $2,686.90.
Silver traded up 0.1% to $32.355 on Friday, while copper fell 0.3% to $4.6245.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX climbed 1.04% and France's CAC 40 jumped 0.49%. Spain's IBEX 35 Index rose 0.21%, while London's FTSE 100 rose 0.23%.
The industry confidence indicator in Spain climbed by 2.8 points from the prior month to a reading of -0.7 in September. Industrial producer prices in Italy declined by 0.8% year-over-year in August.
The economic sentiment indicator in the Eurozone slipped to 96.2 in September from 96.5 in August, while services sentiment indicator climbed to a four-month high level of 6.7 in September. The consumer confidence indicator in the Eurozone gained by 0.5 points to -12.9 in September.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 jumping 2.32%, Hong Kong's Hang Seng Index jumping 3.55%, China's Shanghai Composite Index gaining 2.88% and India's BSE Sensex falling 0.31%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month. The People&#8217;s Bank of China slashed the reserve requirement ratio for banks by 50bps.
Economics
<ul>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $905.7 billion in August compared to a revised 0.2% rise in the prior month.</li>
<li>The U.S. trade deficit in goods narrowed to $94.3 billion in August versus a revised $102.8 billion gap in the previous month.</li>
<li>U.S. personal income rose by 0.2% from the prior month to $24.015 trillion in August compared to a 0.3% gain in the previous month.</li>
<li>Personal spending rose by 0.2% month-over-month in August.</li>
<li>The US core PCE price index increased by 0.1% from the prior month in August compared to market estimates of a 0.2% increase and versus the 0.2% gain in the previous month. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

Markets

BMEA

Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected

On Friday, Acadia Healthcare Company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) agreed to pay $16.6 million to resolve allegations that it violated the False Claims Act by billing federal healthcare programs for unnecessary or non-compliant inpatient behavioral health services.
The company operates facilities across the United States. Four states involved in the case—Florida, Georgia, Michigan, and Nevada—will receive additional settlements of $3.2 million.
The allegations <a target="_blank" href="https://www.justice.gov/opa/pr/acadia-healthcare-company-inc-pay-1985m-settle-allegations-relating-medically-unnecessary" rel="noreferrer noopener">stemmed</a> from Acadia&#8217;s conduct between 2014 and 2017, during which it allegedly admitted patients ineligible for inpatient treatment and kept them longer than necessary.
The United States contended that Acadia failed to provide adequate staffing and supervision, leading to serious harm to patients, including suicides and assaults. Additionally, the company was accused of failing to provide services that met federal and state standards, including insufficient therapy and discharge planning.
As a result, Acadia billed Medicare, Medicaid, and TRICARE for services that did not comply with required regulations.
New York Times report <a target="_blank" href="https://www.nytimes.com/2024/09/26/health/acadia-doj-settlement-fbi.html" rel="noreferrer noopener">noted</a> that the government is investigating Acadia&#8217;s recent practices, as reported by multiple former employees from Georgia and Missouri who have recently spoken with agents from the FBI and the Health and Human Services Department&#8217;s inspector general&#8217;s office.
In Georgia, these employees, who worked in hospital emergency rooms assessing patients&#8217; needs for psychiatric facility referrals, reported that an FBI agent inquired about any pressure they felt to refer patients to Acadia&#8217;s hospitals.
Meanwhile, former nurses from Acadia in Missouri were questioned about the company&#8217;s pressure on them to label patients as uncooperative or combative, which was intended to justify extending their stays.
Robert DeConti, the inspector general&#8217;s chief counsel, stated that the settlement does not impede investigators from exploring allegations regarding more recent activities.
In a separate press release, Acadia Healthcare said the company is cooperating fully with authorities in response to a government investigation recently <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41065747/acadia-healthcare-issues-statement-with-respect-to-government-investigation" rel="noreferrer noopener">disclosed by the company</a>.
Recently, media reports surfaced concerning troubling patient <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39803259/uhs-acadia-healthcare-navigate-scrutiny-amid-safety-concern-allegations-at-psychiatric-hospitals-o" rel="noreferrer noopener">experiences at Acadia&#8217;s facilities</a>.
Acadia&#8217;s Chief Executive Officer, Chris Hunter, addressed these reports, stating they are inconsistent with Acadia&#8217;s policies and do not reflect the medical complexities involved in behavioral healthcare.
Acadia is set to invest an additional $100 million in technology to improve patient and staff safety and enhance care coordination. This includes upgrades like electronic medical records (EMR) systems, wearable remote patient monitoring devices, staff communication and alert tools, and a cloud-based performance improvement platform.
These innovations will offer better transparency and oversight of clinical and quality operations across Acadia&#8217;s facilities.
In an SEC <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1520697/000119312524227393/d856245d8k.htm" rel="noreferrer noopener">filing</a>, Acadia Healthcare said the United States Attorney&#8217;s Office for the Southern District of New York issued a voluntary information request alongside a grand jury subpoena from the United States District Court for the Western District of Missouri.
These inquiries pertain to Acadia&#8217;s admissions processes, patient stay length, and billing practices.
Additionally, Acadia&#8217;s subsidiary received a grand jury subpoena concerning similar issues. Acadia expects to receive additional document requests from the U.S. Securities and Exchange Commission and may encounter further requests from other governmental bodies.
Price Action: ACHC stock is down 26.60% at $55.47 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre" target="_blank" rel="noreferrer noopener">SEC Charges Cassava Sciences Over Manipulated Alzheimer&#8217;s Trial Data, Company And Former Execs Agree To Pay Penalty</a>.</li>
</ul>
Photo by Casimiro PT via Shutterstock

Large Cap

Health Care

Legal

Media

General

Federal Investigations Continue For Psychiatric Hospital Chain Operator Acadia Healthcare Even After $20M Settlement Over False Claims Allegations

U.S. stocks traded higher this morning, with the Dow Jones index rising more than 100 points on Friday.
Following the market opening Friday, the Dow traded up 0.27% to 42,290.97 while the NASDAQ rose 0.16% to 18,218.51. The S&amp;P 500 also rose, gaining, 0.17% to 5,755.11.
Check This Out: <a href="https://www.benzinga.com/news/24/09/41065070/micron-to-150-here-are-10-top-analyst-forecasts-for-friday">Micron To $150? Here Are 10 Top Analyst Forecasts For Friday</a>
Leading and Lagging Sectors Energy shares jumped by 0.8% on Friday.
In trading on Friday, consumer staples shares fell by 0.2%.
Top Headline
Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported upbeat earnings for its fourth quarter, while sales missed expectations.
The company reported quarterly revenue of $79.697 billion, missing the consensus estimate of $79.973 billion. The membership-based retailer reported quarterly earnings of $5.29 per share, beating analyst estimates of $5.08 per share, according to Benzinga Pro.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) shares shot up 109% to $1.21.</li>
<li>Shares of Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) got a boost, surging 78% to $6.03. Altos Venture reported a 32.5% stake in the company as of September 24 in a 13D filing on Thursday.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares were also up, gaining 38% to $1.47.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Seelos Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares dropped 23% to $3.8725. Seelos announced postponement of its annual meeting of stockholders.</li>
<li>Shares of enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) were down 22% to $3.50 after the company announced the pricing of a $15 million public offering of 4.3 million shares at $3.50 per share.</li>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) was down, falling 17% to $62.78 after the company issued a statement stating they are cooperating fully with the authorities regarding a government investigation.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $67.71 while gold traded down 0.1% at $2,694.70.
Silver traded up 0.4% to $32.480 on Friday, while copper fell 0.5% to $4.6170.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.5%, Germany's DAX climbed 1.2% and France's CAC 40 jumped 0.6%. Spain's IBEX 35 Index rose 0.3%, while London's FTSE 100 rose 0.3%.
The industry confidence indicator in Spain climbed by 2.8 points from the prior month to a reading of -0.7 in September. Industrial producer prices in Italy declined by 0.8% year-over-year in August.
The economic sentiment indicator in the Eurozone slipped to 96.2 in September from 96.5 in August, while services sentiment indicator climbed to a four-month high level of 6.7 in September. The consumer confidence indicator in the Eurozone gained by 0.5 points to -12.9 in September.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 jumping 2.32%, Hong Kong's Hang Seng Index jumping 3.55%, China's Shanghai Composite Index gaining 2.88% and India's BSE Sensex falling 0.31%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month. The People&#8217;s Bank of China slashed the reserve requirement ratio for banks by 50bps.
Economics
<ul>
<li>U.S. wholesale inventories increased 0.2% month-over-month to $905.7 billion in August compared to a revised 0.2% rise in the prior month.</li>
<li>The U.S. trade deficit in goods narrowed to $94.3 billion in August versus a revised $102.8 billion gap in the previous month.</li>
<li>U.S. personal income rose by 0.2% from the prior month to $24.015 trillion in August compared to a 0.3% gain in the previous month.</li>
<li>Personal spending rose by 0.2% month-over-month in August.</li>
<li>The U.S. core PCE price index increased by 0.1% from the prior month in August compared to market estimates of a 0.2% increase and versus the 0.2% gain in the previous month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41064318/top-3-real-estate-stocks-that-are-preparing-to-pump-this-month">Top 3 Real Estate Stocks That Are Preparing To Pump This Month</a></li>
</ul>

CNEY

COST

Dow Surges Over 100 Points; Costco Earnings Top Views

WIIM

Acadia Healthcare shares are trading lower after the company issued a statement stating they are cooperating fully with the authorities regarding a government investigation.

Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) issued the following statement with respect to a government investigation separately disclosed today by the Company. Acadia is cooperating fully with the authorities regarding this matter.
"Ensuring we provide the highest quality of care is personal for me and the number one priority for my colleagues across the Company," said Acadia Chief Executive Officer Chris Hunter. "We take seriously our patient care and compliance responsibilities and understand how critical it is to provide these services with excellence and compassion. We're committed to taking action on incidents that fall short of our rigorous standards and are making investments necessary to establish Acadia as the leading behavioral healthcare provider for high-acuity and complex needs patients."
Hunter added, "Over the last two years, we have been investing in new talent, technology, clinical protocols and training across all of our service lines to drive forward our culture of caring. We have also expanded our leadership team to include new roles and expertise critical to providing even safer, higher-quality care – our Chief Quality Officer of Inpatient Services, Chief Compliance Officer, Chief Information Officer, and most recently, our Chief Medical Officer. It will take time for the benefits of our initiatives to be fully realized, but we're already seeing positive results."

Acadia Healthcare Issues Statement With Respect To Government Investigation; Acadia Is Cooperating Fully With The Authorities Regarding This Matter

<a href="https://www.justice.gov/opa/pr/acadia-healthcare-company-inc-pay-1985m-settle-allegations-relating-medically-unnecessary#:~:text=Acadia%20Healthcare%20Company%20Inc.%2C%20a,services%20or%20for%20services%20that">https://www.justice.gov/opa/pr/acadia-healthcare-company-inc-pay-1985m-settle-allegations-relating-medically-unnecessary#:~:text=Acadia%20Healthcare%20Company%20Inc.%2C%20a,services%20or%20for%20services%20that</a>
&nbsp;
Acadia Healthcare Company Inc., a Delaware corporation with its principal place of business in Franklin, Tennessee, has agreed to resolve allegations that it violated the False Claims Act and related state statutes by knowingly billing for medically unnecessary inpatient behavioral health services or for services that did not meet federal and state regulations. Acadia Healthcare Company owns and operates inpatient behavioral health facilities throughout the United States, including The Pavilion at HealthPark LLC, doing business as Park Royal Hospital in Ft. Myers, Florida; Riverwoods Behavioral Health LLC, doing business as Lakeview Behavioral Health in Norcross, Georgia, and as Riverwoods Behavioral Health System in Riverdale, Georgia; Ten Broeck Tampa LLC, doing business as North Tampa Behavioral Health in Wesley Chapel, Florida; PHC of Michigan LLC, doing business as Harbor Oaks Hospital in New Baltimore, Michigan; and Seven Hills Hospital LLC, doing business as Seven Hills Hospital in Henderson, Nevada (collectively, Acadia).
The United States contended that, between 2014 and 2017, Acadia knowingly submitted false claims for payment to Medicare, Medicaid and TRICARE for inpatient behavioral health services that were not reasonable or medically necessary. In particular, the United States contended that Acadia admitted beneficiaries who were not eligible for inpatient treatment and failed to properly discharge beneficiaries when they no longer needed inpatient treatment and had improper and excessive lengths of stay. The United States further alleged that Acadia knowingly failed to provide adequate staffing, training and/or supervision of staff, which resulted in assaults, elopements, suicides and other harm resulting from these staffing failures. In addition, Acadia allegedly failed to provide inpatient acute care in accord with federal and state regulations, including, but not limited to, by failing to provide active treatment, to develop and/or update individualized assessments and treatment plans, to provide adequate discharge planning and to provide required individual and group therapy.
Under the settlement agreement, Acadia will pay $16,663,918 to the United States to resolve its liability under the False Claims Act for its allegedly false Medicare, Medicaid and TRICARE billings. The Medicaid program is jointly funded by the states and the federal government, and pursuant to separate settlement agreements, Acadia will pay an additional $3,186,082 to Florida, Georgia, Michigan and Nevada to resolve their state law claims against Acadia. &nbsp;
"This settlement demonstrates the Justice Department's commitment to ensuring that federal healthcare programs pay only for services that are needed and properly provided," said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department's Civil Division. "It is particularly important that health care providers satisfy these requirements when providing services to a vulnerable patient population, such as residents of an inpatient behavioral health facility."
"Federal health care programs rely upon the honesty and credibility of participating providers," said U.S. Attorney Roger B. Handberg for the Middle District of Florida. "The Justice Department will hold accountable those who seek to exploit these programs for personal gain, jeopardizing the health of patients."
"Medical providers who participate in federally funded health care programs must follow the law when billing Medicare, Medicaid and Tricare," said Special Agent in Charge Tamala E. Miles of the Department of Health and Human Services Office of Inspector General (HHS-OIG). "This settlement illustrates HHS-OIG's commitment to protecting the integrity of these taxpayer-funded programs and the well-being of enrollees seeking treatment. Working closely with the United States Attorney's Office and other law enforcement partners, we will continue to thoroughly investigate such fraudulent billing schemes."
"Billing TRICARE for medically unnecessary inpatient behavioral health services or for services that did not meet federal and state regulations impacts our ability to reimburse providers in a timely manner for care that is needed to keep our military ready to defend the nation," said Rear Admiral Matthew Case of the U.S. Navy and Acting Assistant Director for Health Care Administration for the Defense Health Agency. "We thank our state and federal partners for their work on this case, and the whistleblowers who came forward for their bravery. As a result, we are able to continue delivering one of the most comprehensive and affordable health benefits available to any American."
The settlement includes the resolution of claims brought under the qui tam or whistleblower provisions of the False Claims Act by Franka Tirado, Brian Snyder and Jamie Thompson, all former employees of Acadia. Under those provisions, a private party can file an action on behalf of the United States and receive a portion of any recovery. The qui tam cases are captioned U.S. ex rel. Tirado, et al. v. Park Royal Hospital et al., Case No. 2:17-cv-201-FtM-99 (MDFL), and U.S. ex rel. Thompson v. Acadia Healthcare Company Inc., et al., Case No. 2:18-cv-543-FtM-38CM (MDFL). The whistleblower share of the federal portion of the settlement will be $3,166,144.42.
The resolution obtained in this matter was the result of a coordinated effort between the Civil Division's Commercial Litigation Branch, Fraud Section, and U.S. Attorney's Office for the Middle District of Florida, as well as the National Association of Medicaid Fraud Control Units, with assistance from HHS-OIG and the Department of Defense Criminal Investigative Service.
The investigation and resolution of this matter illustrates the government's emphasis on combating health care fraud. One of the most powerful tools in this effort is the False Claims Act. Tips and complaints from all sources about potential fraud, waste, abuse and mismanagement can be reported to HHS at 800-HHS-TIPS (800-447-8477).
Senior Trial Counsel Sarah Arni of the Civil Division's Fraud Section and former Senior Litigation Counsel Lindsay Griffin for the Middle District of Florida handled the matter.
The claims resolved by the settlements are allegations only. There has been no determination of liability.
<a href="https://www.justice.gov/media/1370996/dl">Settlement</a>

CORRECTION: Acadia Healthcare Company To Pay $19.85M To Settle Allegations Relating To Medically Unnecessary Inpatient Behavioral Health Services

In the preceding three months, 10 analysts have released ratings for Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Acadia Healthcare Co, presenting an average target of $88.2, a high estimate of $94.00, and a low estimate of $75.00. Highlighting a 0.11% decrease, the current average has fallen from the previous average price target of $88.30. 
<img src="https://www.benzinga.com/files/images/story/2024/1726858904_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Acadia Healthcare Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Acadia Healthcare Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Acadia Healthcare Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Acadia Healthcare Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Acadia Healthcare Co: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Acadia Healthcare Co's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 8.85%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Acadia Healthcare Co's ROE excels beyond industry benchmarks, reaching 2.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Acadia Healthcare Co's ROA excels beyond industry benchmarks, reaching 1.4%. This signifies efficient management of assets and strong financial health.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Acadia Healthcare Co Stock

RBC Capital analyst Ben Hendrix reiterates Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Outperform and maintains $94 price target.

Price Target

Reiteration

RBC Capital Reiterates Outperform on Acadia Healthcare Co, Maintains $94 Price Target

U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 100 points on Tuesday.
Shares of Dyne Therapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NYSE">DYN</a>) fell sharply in today's pre-market trading after the company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement <a href="https://www.benzinga.com/quote/DYN">in multiple cohorts.</a>
Dyne Therapeutics shares dipped 15.6% to $38.89 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Acadia Healthcare Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares fell 7.2% to $76.07 in pre-market trading.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares fell 5.8% to $35.70 in pre-market trading. Vice President Kamala Harris has expressed her support for American ownership of United States Steel, amidst ongoing foreign acquisition attempts.</li>
<li>Diversified Energy Company PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) fell 5.6% to $11.54 in pre-market trading. Keybanc analyst Tim Rezvan, last week, initiated coverage on Diversified Energy with an Overweight rating and announced a price target of $18.</li>
<li>LG Display Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPL#NYSE">LPL</a>) shares fell 4.4% to $3.96 in pre-market trading.</li>
<li>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) shares declined 4.1% to $2.60 in pre-market trading.</li>
<li>Hafnia Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NASDAQ">HAFN</a>) fell 4.1% to $7.43 in pre-market trading.</li>
<li>BHP Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) shares fell 4% to $52.90 in pre-market trading</li>
<li>Hafnia Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NYSE">HAFN</a>) fell 3.4% to $7.48 in pre-market trading.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares declined 3.2% to $21.78 in pre-market trading. PureTech Health, last week, reported a year-over-year decrease in H1 financial results.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares slipped 2.6% to $169.15 in pre-market trading  ahead of the Sept. 12 expiration of the company&#8217;s contract with the International Association of Machinists, which could lead to a potential strike. Additionally, Wells Fargo downgraded the stock from Equal-Weight to Underweight..</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Pre-Market Outlook

ALTM

HAFN

PRTC

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Acadia Healthcare Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achc#NASDAQ">ACHC</a>) and Methodist Jennie Edmundson Hospital recently conducted a groundbreaking ceremony for a cutting-edge behavioral health hospital in Council Bluffs, IA. Plans to establish the hospital were announced in July 2023 as part of the joint-venture partnership between ACHC and Omaha-based Methodist Health System. The Methodist Jennie Edmundson Hospital is part of Methodist Health System.&nbsp;
The new facility will be named Methodist Jennie Edmundson Behavioral Health and is likely to commence operations in 2026. It will feature 96 inpatient beds, with 24 specifically designated for addressing the mental health needs of children and adolescents. It will also offer intensive outpatient services. The hospital will invest in cutting-edge technology and resources to enhance access to high-quality behavioral health services for patients dealing with acute mental health and substance use disorders.
This, in turn, is expected to bring about improved health outcomes for residents of western Iowa and eastern Nebraska. Working closely with local organizations, hospitals and first responders of the two regions will enable the joint venture partners to better serve the targeted regions.
<h2>A Time-Opportune Move on ACHC&#39;s Part</h2>
Opening the Methodist Jennie Edmundson Behavioral Health Hospital is likely to be a time-opportune move considering the dire need for acute and intensive outpatient behavioral health services across the Council Bluffs community. According to the American Hospital Directory, there remains a shortage of more than 300 inpatient behavioral health beds in Iowa and Nebraska, which further substantiates the timeliness of the recent move.
<h2>Benefits to Acadia Healthcare</h2>
New facilities resulting from joint ventures offer a means for ACHC to serve a greater number of patients and earn more revenues.&nbsp;
Acadia Healthcare often resorts to buyouts or joint ventures with renowned U.S. health systems to inaugurate new hospitals or expand existing facilities through bed additions. Its healthcare portfolio comprised 258 behavioral healthcare facilities across 38 states and Puerto Rico as of June 30, 2024. Management anticipates adding more than 400 beds to existing facilities in 2024.
<h2>ACHC Stock&#39;s Price Performance</h2>
Shares of Acadia Healthcare have gained 19.2% in the past month compared with the industry&#39;s 8.5% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4d/75809.jpg?v=356746199" />
Image Source: Zacks Investment Research
<h2>Zacks Rank &amp; Key Picks</h2>
ACHC currently carries a Zacks Rank #3 (Hold).&nbsp;
Some better-ranked stocks in the Medical space are LeMaitre Vascular, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmat#NASDAQ">LMAT</a>)&nbsp;, Avanos Medical, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/avns#NYSE">AVNS</a>) and The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>). While LeMaitre Vascular sports a Zacks Rank #1 (Strong Buy), Avanos Medical and Ensign Group carry a Zacks Rank #2 (Buy) at present.
LeMaitre Vascular&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 8.87%. The Zacks Consensus Estimate for LMAT&#39;s 2024 earnings implies an improvement of 37% while the same for revenues indicates growth of 13% from the respective 2023 figures.
The Zacks Consensus Estimate for LMAT&#39;s&nbsp; earnings has moved 4.5% north in the past 30 days. Shares of LeMaitre Vascular have gained 2.4% in the past month.
Avanos Medical&#39;s earnings surpassed estimates in three of the last four quarters and missed the mark once, the average surprise being 5.69%. The Zacks Consensus Estimate for AVNS&#39; 2024 earnings indicates a 35% rise from the 2023 figure.
The consensus mark for AVNS&#39;&nbsp; earnings has moved 0.7% north in the past 30 days. Shares of Avanos Medical have gained 6.1% in the past month.
Ensign Group&#39;s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 1.40%. The Zacks Consensus Estimate for ENSG&#39;s 2024 earnings indicates an 14.1% rise while the same for revenues implies an improvement of 13.1% from the respective 2023 reported figures.&nbsp;
The consensus mark for ENSG&#39;s earnings has moved up 0.7% in the past 30 days.&nbsp; Shares of Ensign Group have gained 1.8% in the past month.
<a href="https://www.zacks.com/stock/news/2328512/acadia-healthcare-expands-behavioral-health-services-in-iowa?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2328512">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Mid Cap

Small Cap

Management

AVNS

ENSG

LMAT

Acadia Healthcare Expands Behavioral Health Services in Iowa

Cantor Fitzgerald analyst Sarah James reiterates Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Neutral and maintains $90 price target.

Cantor Fitzgerald Reiterates Neutral on Acadia Healthcare Co, Maintains $90 Price Target

Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.0, a high estimate of $94.00, and a low estimate of $75.00. A decline of 0.12% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1724086828_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Acadia Healthcare Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Acadia Healthcare Co's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Acadia Healthcare Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Acadia Healthcare Co's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Acadia Healthcare Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.85% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Acadia Healthcare Co's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.86%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Acadia Healthcare Co's ROE excels beyond industry benchmarks, reaching 2.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.4%, the company showcases effective utilization of assets.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Acadia Healthcare Co

Acadia Healthcare Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NYSE">ACHC</a>) short percent of float has fallen 6.19% since its last report. The company recently reported that it has 3.58 million shares sold short, which is 3.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Acadia Healthcare Co Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723058110_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Acadia Healthcare Co has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Acadia Healthcare Co's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Acadia Healthcare Co's peer group average for short interest as a percentage of float is 6.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Acadia Healthcare Co's Recent Short Interest

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares jumped 65.95%. The company reached a supply agreement with Corning for next-generation fiber-optic cables to <a href="https://www.benzinga.com//node/40104952" target="_blank" rel="noreferrer noopener">support AI demands in data centers</a>.</li>
<li>Shake Shack, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) shares escalated 19.52% after the company reported <a href="https://www.benzinga.com//node/40104675" target="_blank" rel="noreferrer noopener">better-than-expected Q2 sales results</a>. Several analysts increased <a href="https://www.benzinga.com//node/40131307" target="_blank" rel="noreferrer noopener">their forecasts for the company</a>.</li>
<li>Parsons Corp NYSE: PSN) stock gained 15.42% after it reported better-than-expected Q2 results and raised its FY24 revenue outlook.</li>
<li>Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) stock increased 15.23% after the company reported better-than-expected Q2 sales results and issued Q3 and FY24 <a href="https://www.benzinga.com//node/40081350" target="_blank" rel="noreferrer noopener">revenue guidance above estimates</a>.</li>
<li>Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) stock upped 15.14%. The company reported <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40044492/repligen-lowers-guidance-on-china-weakness-analyst-expects" target="_blank" rel="noreferrer noopener">Q2 earnings</a>, after which several analysts revised their price forecasts.</li>
<li>Frontdoor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) stock gained 15.09% following better-than-expected Q2 earnings.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock upped 14.47% after the company reported better-than-expected Q2 financial results and <a href="https://www.benzinga.com//node/40021917" target="_blank" rel="noreferrer noopener">raised its FY24 revenue guidance</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40150484/microstrategy-intel-and-moderna-are-among-top-12-large-cap-losers-last-week-july-28-august-3-are-the" target="_blank" rel="noreferrer noopener">MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/24/08/40150236/doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-other" target="_blank" rel="noreferrer noopener">DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by YAO23 via Shutterstock

CVLT

CWAN

DRVN

FTDR

HWKN

IDCC

LUMN

RGEN

SHAK

ZETA

Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?

Deutsche Bank analyst Pito Chickering maintains Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) with a Hold and raises the price target from $70 to $75.

Deutsche Bank Maintains Hold on Acadia Healthcare Co, Raises Price Target to $75

Throughout the last three months, 9 analysts have evaluated Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $89.67, a high estimate of $94.00, and a low estimate of $83.00. Highlighting a 2.18% decrease, the current average has fallen from the previous average price target of $91.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1722614465_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Acadia Healthcare Co by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$91.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Acadia Healthcare Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Acadia Healthcare Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Acadia Healthcare Co's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>Get to Know Acadia Healthcare Co Better</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Acadia Healthcare Co: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Acadia Healthcare Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.06% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Acadia Healthcare Co's ROE stands out, surpassing industry averages. With an impressive ROE of 2.7%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Acadia Healthcare Co's ROA excels beyond industry benchmarks, reaching 1.4%. This signifies efficient management of assets and strong financial health.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below the industry average at 0.69, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Acadia Healthcare Co Through The Eyes Of 9 Analysts

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cencora (COR – Research Report), Acadia Healthcare (...

Analysts Are Bullish on Top Healthcare Stocks: Cencora (COR), Acadia Healthcare (ACHC)

ClearBridge Small Cap Value Strategy Q2 2024 Commentary

Invesco Small Cap Growth Fund Q2 2024 Review

Small-cap and mid-cap Health Care has room to rally - Roth MKM

Acadia Healthcare is holding patients against their will to increase insurance payouts: NYT

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

RBC Capital analyst Ben Hendrix maintained a Buy rating on Acadia Healthcare (ACHC – Research Report) yesterday and set a price target of $94.00. T...

Comments

Acadia Healthcare Co

Noticias

Últimas noticias sobre Acadia Healthcare Co (NASDAQ:ACHC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL